TGT Stock Recent News
TGT LATEST HEADLINES
Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT 48-week EOT data from Cohort 1-3 of the ENSURE study clearly suggests the added benefits of elebsiran towards achieving a higher rate of HBsAg loss in combination with PEG-IFNα DURHAM, N.C. and BEIJING, China , March 30, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the 34th Annual Meeting of Asian Pacific Association for the Study of the Liver (APASL 2025) in Beijing, China.
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Target Corporation ("Target" or "the Company") (NYSE:TGT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Target securities between March 9, 2022 and November 19, 2024, both dates inclusive (the "Class Period").
NEW YORK, NY / ACCESS Newswire / March 29, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Target Corporation (NYSE:TGT) between August 26, 2022 and November 19, 2024, both dates inclusive (the "Class Period"), of the important April 1, 2025 lead plaintiff deadline. SO WHAT: If you purchased Target common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Travelers (TRV) remains a buy due to strong quarterly results, resilient performance, and favorable valuation despite recent market pressures and extreme weather events. TRV's Q4 non-GAAP EPS of $9.15 beat forecasts by $2.54, with revenue up 20% YoY, driven by strong homeowners insurance margins. Key risks include the financial impact of LA wildfires, macro uncertainties, and insurance inflation, but TRV's pricing power and technical chart are encouraging.
NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Target Corporation (NYSE: TGT) between August 26, 2022 and November 19, 2024, both dates inclusive (the “Class Period”), of the important April 1, 2025 lead plaintiff deadline.
Despite recession fears and negative sentiment surveys, historical data and fundamentals indicate strong potential for stock market gains. Sentiment surveys are unreliable due to social media algorithms. Hard economic data shows steady growth, suggesting consumer spending remains robust and recession fears are overblown. Dividend aristocrats, with their long-term dividend growth and coiled spring valuations, offer significant upside potential, making them smart investments for the next year.
NEW YORK , March 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Target Corporation (NYSE: TGT) between August 26, 2022 and November 19, 2024, both dates inclusive (the "Class Period"), of the important April 1, 2025 lead plaintiff deadline. So what: If you purchased Target common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Investors rarely get a chance to pile into some of the United States' leading names in the economy at discounts. Today's opportunity comes within the retail sector, as a specific name has gone down to low prices not seen since the onset of the COVID-19 pandemic outbreak, making this opportunity a proverbial no-brainer buying potential moving forward into the rest of the year.
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Target Corporation ("Target" or "the Company") (NYSE:TGT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Target securities between March 9, 2022 and November 19, 2024, both dates inclusive (the "Class Period").
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Target Corporation (“Target” or “the Company”) (NYSE: TGT) and certain of its officers.